Detailed Narrative
BD Excellence Driving Margin Expansion
BD's lean operating system, BD Excellence, continues to be a key enabler of strong margin execution. In Q3, it delivered an adjusted gross margin of 54.8%, up 50 basis points year-over-year, and an adjusted operating margin of 25.8%, up 60 basis points year-over-year. This initiative has reduced manufacturing waste by over 35% and significantly increased Overall Equipment Effectiveness (OEE), creating capacity to produce an additional 2.5 billion units on existing production lines. Customer service levels, measured by on-time in full deliveries (OTIF), reached their highest level in over five years, demonstrating operational improvements.
Strategic Separation of Biosciences and Diagnostic Solutions
BD announced a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters through a tax-efficient Reverse Morris Trust. This transaction is progressing well towards an expected closing around the end of the first quarter of calendar year 2026. The separation is anticipated to unlock meaningful value for shareholders and establish 'New BD' as a scaled, pure-play medical technology company with a best-in-class consumable revenue profile exceeding 90%, a deep innovation pipeline, and strong margin expansion fueled by BD Excellence.
Innovation Pipeline Advancements Across Segments
The company highlighted several key product launches and milestones. In Life Sciences, the FACSDiscover A8 flow cytometer saw strong traction, and a 'Made in China for China' clinical analyzer is launching. For Diagnostics, the next-generation BACTEC is expected in FY26, and the BD COR platform for HPV testing includes an at-home self-collection kit submitted to the FDA, with approval expected mid-FY26. In Medical, the BD Libertas Wearable Injector entered its first pharma-sponsored clinical trial, and CentroVena One, a rapid insertion central catheter, received FDA clearance and is launching this quarter.
Connected Care and AI Integration Initiatives
BD is advancing its connected care solutions with the limited commercial release of the new BD Pyxis Pro, a redesigned hardware platform, and the upcoming launch of BD Incada enterprise AI software. Pyxis Pro is the first product line to feed data into the Incada AI platform, with future integration planned for Alaris and HemoSphere Alta Monitor. These initiatives aim to improve nurse workflow, enhance drug availability, and transform productivity using artificial intelligence, representing a significant long-term journey for the company.
Interventional Segment Expansion and Urology Growth
The Interventional segment is expanding indications for its advanced tissue regeneration platform. The Phasix resorbable scaffold recently launched in Europe to prophylactically prevent incisional hernias, a condition affecting up to 50% of high-risk patients after laparotomies. A U.S. clinical trial for this indication is ongoing, with full patient enrollment anticipated in FY26. The Urology and Critical Care (UCC) business continues its strong momentum, driven by the successful scaling of PureWick Male and the expansion of PureWick into the home setting, with new mobile versions planned for launch.
Proactive Tariff Mitigation Efforts
BD is actively working to mitigate the impact of tariffs, which are expected to be $90 million for FY25 and an anticipated $275 million for FY26. Mitigation strategies include changing sourcing flows for products like Vacutainer and flush to markets outside the U.S. for China, modifying components and kits to comply with USMCA and tariff exemptions, and optimizing supplier locations. These efforts have led to a notable improvement in the FY26 tariff outlook compared to initial expectations.